PD-L1 monoclonal antibody treats ischemic stroke by controlling central nervous system inflammation

Stroke

Volumn 46, Issue 10, 2015, Pages 2926-2934

  Bodhankar, Sheetal ^a,b   Chen, Yingxin ^b   Lapato, Andrew ^a,b   Dotson, Abby L ^a,b   Wang, Jianming ^b   Vandenbark, Arthur A ^a,b   Saugstad, Julie A ^b,c   Offner, Halina ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Anti PD L1 antibody therapy; Interleukin 10; Middle cerebral artery occlusion; Reperfusion; Stroke

Indexed keywords

GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CD8+ T LYMPHOCYTE; CELL POPULATION; CENTRAL NERVOUS SYSTEM INFLAMMATION; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FLOW CYTOMETRY; HEMISPHERE; IMMUNOFLUORESCENCE; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CEREBRAL ARTERY DISEASE; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BRAIN; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; MICE, INBRED C57BL; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY;

EID: 84942905088     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.010592     Document Type: Article

References (30)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397.
2. Lakhan SE, Kirchgessner A, Hofer M. Infammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009;7:97. doi: 10.1186/1479-5876-7-97.
3. Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysi-ologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004;24:351-371. doi: 10.1097/00004647-200404000-00001.
4. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808. doi: 10.1038/nm.2399.
5. Macrez R, Ali C, Toutirais O, Le Mauff B, Defer G, Dirnagl U, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-480. doi: 10.1016/S1474-4422(11)70066-7.
6. Hurn PD, Subramanian S, Parker SM, Afentoulis ME, Kaler LJ, Vandenbark AA, et al. T-and B-cell-defcient mice with experimental stroke have reduced lesion size and infammation. J Cereb Blood Flow Metab. 2007;27:1798-1805. doi: 10.1038/sj.jcbfm.9600482.
7. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835-3842. doi: 10.1182/blood-2009-10-249078.
8. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammad-eltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946-950. doi: 10.1038/nm.1999.
9. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105-2112. doi: 10.1161/CIRCULATIONAHA.105.593046.
10. Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. Programmed death-1 pathway limits central nervous system infammation and neurologic defcits in murine experimental stroke. Stroke. 2011;42:2578-2583. doi: 10.1161/STROKEAHA.111.613182.
11. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. PD-L1 enhances CNS infammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinfammation. 2013;10:111. doi: 10.1186/1742-2094-10-111.
12. Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Offner H. Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. Front Cell Neurosci. 2014;8:228. doi: 10.3389/fncel.2014.00228.
13. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA. 2003;100:5336-5341. doi: 10.1073/pnas.0931259100.
14. Ibrahim R, Stewart R, Shalabi A. PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol. 2015;42:474-483. doi: 10.1053/j. seminoncol.2015.02.007.
15. Chen Y, Bodhankar S, Murphy SJ, Vandenbark AA, Alkayed NJ, Offner H. Intrastriatal B-cell administration limits infarct size after stroke in B-cell defcient mice. Metab Brain Dis. 2012;27:487-493. doi: 10.1007/s11011-012-9317-7.
16. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. IL-10-producing B-cells limit CNS infammation and infarct volume in experimental stroke. Metab Brain Dis. 2013;28:375-386. doi: 10.1007/s11011-013-9413-3.
17. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26:654-665. doi: 10.1038/sj.jcbfm.9600217.
18. Campanella M, Sciorati C, Tarozzo G, Beltramo M. Flow cyto-metric analysis of infammatory cells in ischemic rat brain. Stroke. 2002;33:586-592.
19. Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176:6523-6531.
20. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238:53-56.
21. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360-366. doi: 10.1097/00004647-199605000-00002.
22. Schroeter M, Jander S, Witte OW, Stoll G. Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol. 1994;55:195-203.
23. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-122. doi: 10.1016/j.immuni.2007.05.016.
24. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood. 2010;116:1291-1298. doi: 10.1182/blood-2010-01-265975.
25. Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. J Neuroinfammation. 2011;8:155. doi: 10.1186/1742-2094-8-155.
26. Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, et al. The programmed death-1 ligand 1:B7-1 pathway restrains dia-betogenic effector T cells in vivo. J Immunol. 2011;187:1097-1105. doi: 10.4049/jimmunol.1003496.
27. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465. doi: 10.1056/NEJMoa1200694.
28. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242. doi: 10.1111/j.1600-065X.2010.00923.x.
29. Bodhankar S, Chen Y, Lapato A, Vandenbark AA, Murphy SJ, Saugstad JA, et al. Regulatory CD8(+)CD122 (+) T-cells predominate in CNS after treatment of experimental stroke in male mice with IL-10-secreting B-cells. Metab Brain Dis. 2015;30:911-924. doi: 10.1007/s11011-014-9639-8.
30. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. Treatment of experimental stroke with IL-10-producing B-cells reduces infarct size and peripheral and CNS infammation in wild-type B-cell-suffcient mice. Metab Brain Dis. 2014;29:59-73. doi: 10.1007/s11011-013-9474-3.